Table 2.
Therapeutic agents used in experimental models of sepsis as HSP modulators.
| Therapeutic Agent | Protocol (Pre/Post-Sepsis) | Dosage | Sepsis Model | HSP Expression |
|---|---|---|---|---|
| Glutamine [109] | 1 h (post) | [400 mg/Kg] i.v. | CLP | ↑ |
| Glutamine [110] | 5 min (post) | [750 mg/Kg] i.v. | LPS | ↑ |
| Glutamine [111] | 10–20 min (post) | [750 mg/Kg] i.v. | LPS | ↑ |
| Glutamine [107] | 7 days (pre) | [1.346 mg/Kg] i.p. | LPS | ↑ |
| L-Glutamine [19] | 2 h, 24 h and 45 h (post) | [1000 mg/Kg] oral | LPS | −− |
| Sodium Arsenite [27] | 8 h (post) | [6 mg/Kg] i.v. | CLP | ↑ |
| DHEA [113] | 6 h (post) | [20 mg/Kg] s.c. | CLP | ↑ |
| Celastrol [115] | 30 min (pre) | [1 mg/Kg] i.v. | LPS | ↑ |
| Zinc [28] | 5 days (pre) | [3 mg/Kg] i.p. | LPS | ↑ |
| Curcumin [20] | 7 days (pre)/2 h (post) | [100 mg/Kg] oral | CLP | ↑ |
CLP: cecal ligation and puncture; LPS: injection of lipopolysaccharide; i.v.: intravenous; i.p.: intraperitoneal; s.c.: subcutaneous; ↑ increased expression; −− no change.